Abstract

Background

Standardized response criteria for evaluating patients radiological imaging have an essential role in oncological management. Immunotherapy, using immune checkpoint inhibitors (ICIs), including drugs targeting cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death protein 1 or its ligand, promise a new role that has demonstrated improvement management in cancers resistant to chemotherapy. This article reviews the literature to understand the most useful response evaluation criteria for optimal patient management under immunotherapy treatment. Areas that warrant further research are described.

Conclusion

In conclusion, ICIs have become more widely accepted and used by medical oncologists. Radiologists face challenges in assessing tumor response and becoming more involved in the management of treatment. The latest published immune-RECIST criteria can be used in response assessment, but further prospective evaluation is needed with registration clinical trials to be definitively validated.

Details

Title
Are radiologists ready to evaluate true response to immunotherapy?
Author
Yirgin, Inci Kizildag 1   VIAFID ORCID Logo  ; Erturk, Sukru Mehmet 2   VIAFID ORCID Logo  ; Dogan Izzet 3   VIAFID ORCID Logo  ; Vatansever Sezai 3   VIAFID ORCID Logo 

1  Istanbul University, Department of Radiology, Oncology Institute, Istanbul, Turkey (GRID:grid.9601.e) (ISNI:0000 0001 2166 6619) 
2  Istanbul University, Department of Radiology, Istanbul Medical Faculty, Istanbul, Turkey (GRID:grid.9601.e) (ISNI:0000 0001 2166 6619) 
3  Istanbul University, Department of Medical Oncology, Oncology Institute, Istanbul, Turkey (GRID:grid.9601.e) (ISNI:0000 0001 2166 6619) 
Publication year
2021
Publication date
Feb 2021
Publisher
Springer Nature B.V.
e-ISSN
18694101
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s13244-021-00968-w
ProQuest document ID
2492796918
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.